Amneal Approval Leads Lannett To Job Losses
US Firm Will Consolidate R&D Operation
Around 80 more jobs are to go at Lannett, as the company reels from rival Amneal bagging US Food and Drug Administration approval for the company’s top seller.
You may also be interested in...
Lannett has struck a deal giving it exclusive US distribution rights for 10 years to a generic version of Advair Diskus being developed by China’s Respirent.
Lannett will slash its workforce by around a fifth, representing more than 250 employees, as part of an ongoing cost-reduction plan that is geared towards reducing company expenses by approximately US$66 million on an annualised basis by its financial year ending in June 2020.
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.